Imunon, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Filing reports Item 5.02 disclosure regarding departure or appointment of officers and/or directors, with compensatory arrangements. No specific names, dollar amounts, dates of departure/appointment, share counts, or compensation details are provided in the accessible filing header or metadata. The full substantive text of Item 5.02 is not reproduced in the extracted data available.
Why this rating
Standard Item 5.02 disclosure (routine for public companies); no quantified financial impact evident from available text. At $21.2M market cap, officer changes could matter, but specifics absent.
Extracted items
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.